Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia

医学 柔红霉素 诱导化疗 随机对照试验 内科学 白血病 肿瘤科 外科 化疗
作者
Christoph Röllig,Björn Steffen,Christoph Schliemann,Jan‐Henrik Mikesch,Nael Alakel,Regina Herbst,Mathias Hänel,Richard Noppeney,Maher Hanoun,Martin Kaufmann,Barbora Weinbergerová,Kerstin Schäfer‐Eckart,Tim Sauer,Andreas Neubauer,Andreas Burchert,Claudia Dorothea Baldus,Jolana Mertová,Edgar Jost,Dirk Niemann,Jan Novák
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (1): 65-74 被引量:17
标识
DOI:10.1200/jco.24.00235
摘要

PURPOSE To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60 mg/m 2 with 90 mg/m 2 daunorubicin in the first 7 + 3 induction and one versus two cycles of 7 + 3 induction. PATIENTS AND METHODS Patients age 18-65 years with newly diagnosed AML were randomly assigned to 60 versus 90 mg/m 2 daunorubicin once daily plus cytarabine. Patients with marrow blasts below 5% on day 15 after first induction were randomly assigned to receive a second induction cycle or no second induction cycle. RESULTS Eight hundred and sixty-four patients with a median age of 52 years were randomly assigned. After a preplanned interim analysis showing no significant difference in response between 60 and 90 mg/m 2 , all consecutive patients received 60 mg/m 2 daunorubicin once daily. The proportion of good early responders was 44% versus 48% ( P = .983) with a composite complete remission (CRc) rate of 90% versus 89% after induction ( P = .691); the 3-year relapse-free survival (RFS) after 60 versus 90 mg/m 2 once daily was 54% versus 50% ( P = .561), and the 3-year overall survival (OS) was 65% versus 58% ( P = .242). Among 389 good responders, CRc rates at the end of induction were 87% after single induction and 85% after double induction. The 3-year RFS was 51% versus 60% (hazard ratio [HR], 1.3; P = .091), and the 3-year OS was 76% versus 75% after single versus double induction (HR, 1.0; P = .937). CONCLUSION The use of 90 mg/m 2 daunorubicin once daily in the context of classical 7 + 3 induction does not significantly improve early response and does not lead to higher remission rates or longer survival than 60 mg/m 2 once daily. In patients with a good early response after first induction, a second induction has only a limited impact on RFS and does not result in an OS benefit.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
韦韦完成签到 ,获得积分10
刚刚
dawntiann发布了新的文献求助10
刚刚
1秒前
默z完成签到,获得积分10
1秒前
充电宝的应助被荣荣采纳,获得10
1秒前
咕咚完成签到,获得积分10
1秒前
子画三心完成签到,获得积分10
1秒前
爱睡觉的猫完成签到,获得积分10
2秒前
灵活的胖子wxp完成签到,获得积分0
2秒前
七只鱼完成签到,获得积分10
2秒前
微笑煎蛋发布了新的文献求助10
2秒前
喜欢完成签到,获得积分10
2秒前
2秒前
顽石完成签到,获得积分10
2秒前
拜斯尔完成签到,获得积分10
2秒前
典雅的黑猫完成签到,获得积分10
3秒前
再坚持一点完成签到,获得积分10
3秒前
风趣的鸡翅完成签到,获得积分10
3秒前
molihuakai的应助被wwww采纳,获得30
3秒前
bzzx发布了新的文献求助10
3秒前
星辰大海的应助被GIK尘采纳,获得10
4秒前
好运时间完成签到 ,获得积分10
4秒前
收声完成签到,获得积分10
4秒前
海洋完成签到,获得积分10
4秒前
小二郎的应助被yfy采纳,获得10
4秒前
weiyi发布了新的文献求助10
4秒前
blUe发布了新的文献求助10
4秒前
YWL完成签到,获得积分10
5秒前
JamesPei的应助被武科大采纳,获得10
5秒前
老年人完成签到,获得积分10
5秒前
yurihuang发布了新的文献求助10
5秒前
6秒前
科研通AI6.4的应助被Ttttt采纳,获得10
6秒前
付123完成签到 ,获得积分10
6秒前
songif发布了新的文献求助10
6秒前
nan完成签到,获得积分20
6秒前
冰糖橙完成签到 ,获得积分10
6秒前
秀丽天德完成签到,获得积分10
6秒前
DuanJN完成签到,获得积分10
6秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159542
求助须知:如何正确求助?哪些是违规求助? 9555044
关于积分的说明 21724263
捐赠科研通 7749434
什么是DOI,文献DOI怎么找? 3427246
关于科研通互助平台的介绍 2552263
邀请新用户注册赠送积分活动 2471618